These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16567664)

  • 1. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
    Scott PA; Silbergleit R
    Stroke; 2006 Apr; 37(4):943-4; author reply 944. PubMed ID: 16567664
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
    Demaerschalk BM; Yip TR
    Stroke; 2005 Nov; 36(11):2500-3. PubMed ID: 16224087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
    Leppert MH; Campbell JD; Simpson JR; Burke JF
    Stroke; 2015 Jul; 46(7):1870-6. PubMed ID: 26012639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke.
    Berkowitz AL; Mittal MK; McLane HC; Shen GC; Muralidharan R; Lyons JL; Shinohara RT; Shuaib A; Mateen FJ
    Int J Stroke; 2014 Apr; 9(3):349-55. PubMed ID: 24207029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
    Quinn TJ; Dawson J
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):513-22. PubMed ID: 19941428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers.
    Barnbaum D; Wickstrom G; Clough L
    Stroke; 2001 Oct; 32(10):2440. PubMed ID: 11588341
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
    Ganesalingam J; Pizzo E; Morris S; Sunderland T; Ames D; Lobotesis K
    Stroke; 2015 Sep; 46(9):2591-8. PubMed ID: 26251241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke.
    Shuayto MI; Lopez JI; Greiner F
    J Child Neurol; 2006 Jul; 21(7):604-6. PubMed ID: 16970853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
    Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
    Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator.
    Jain SV; Morton LD
    Pediatr Neurol; 2008 Feb; 38(2):126-9. PubMed ID: 18206794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant tissue plasminogen activator for acute ischemic stroke.
    Al-Buhairi AR; Jan MM
    Saudi Med J; 2002 Jan; 23(1):13-9. PubMed ID: 11938357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
    Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
    Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
    Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
    Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
    Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
    Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
    Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
    Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current indications and results of thrombolysis by intravenous recombinant tissue plasminogen activator.
    Tari Capone F; Cavallari M; Casolla B; Orzi F
    Tech Vasc Interv Radiol; 2012 Mar; 15(1):10-8. PubMed ID: 22464298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada.
    Yip TR; Demaerschalk BM
    Stroke; 2007 Jun; 38(6):1952-5. PubMed ID: 17478740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke.
    Nadareishvili Z; Oh P; Smurawska LT; Tran C; Norris JW
    Neurology; 1999 Mar; 52(4):895-6. PubMed ID: 10078763
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke.
    Riggs JE
    Neurology; 1999 Mar; 52(4):895; author reply 895-6. PubMed ID: 10078762
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.